Zoetis Inc. (NYSE:ZTS – Get Free Report) announced a quarterly dividend on Thursday, October 10th, Wall Street Journal reports. Shareholders of record on Thursday, October 31st will be paid a dividend of 0.432 per share on Tuesday, December 3rd. This represents a $1.73 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend is Thursday, October 31st.
Zoetis has increased its dividend by an average of 23.3% per year over the last three years and has increased its dividend annually for the last 13 consecutive years. Zoetis has a payout ratio of 26.8% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Zoetis to earn $6.43 per share next year, which means the company should continue to be able to cover its $1.73 annual dividend with an expected future payout ratio of 26.9%.
Zoetis Stock Down 0.1 %
Shares of ZTS stock opened at $190.11 on Friday. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. Zoetis has a 1 year low of $144.80 and a 1 year high of $201.92. The firm’s fifty day moving average price is $188.07 and its two-hundred day moving average price is $176.12. The firm has a market capitalization of $86.13 billion, a P/E ratio of 37.20, a PEG ratio of 2.95 and a beta of 0.89.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on ZTS. Piper Sandler lifted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research lifted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. lifted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday. Stifel Nicolaus lifted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $221.44.
Read Our Latest Research Report on ZTS
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Further Reading
- Five stocks we like better than Zoetis
- Retail Stocks Investing, Explained
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- EV Stocks and How to Profit from Them
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- What is the Dow Jones Industrial Average (DJIA)?
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.